Comparison
Semaglutide vs Tirzepatide
The two most prescribed weight loss peptides compared head-to-head.
Reviewed by Dr. Sarah Mitchell, PharmD
Mechanism
GLP-1 agonist (single receptor)
GIP + GLP-1 dual agonist
Avg Weight Loss
~15% body weight
~20–22% body weight
FDA Status
Approved (Ozempic, Wegovy, Rybelsus)
Approved (Mounjaro, Zepbound)
Dosing
Weekly injection or daily oral
Weekly injection only
Half-Life
~7 days
~5 days
Nausea (common SE)
Moderate
Moderate-to-high initially
Cardiovascular Data
Strong CV outcome data (SELECT trial)
CV outcome trials ongoing
Cost (brand)
$900–1,300/month
$1,000–1,400/month
Our Verdict
Tirzepatide delivers greater weight loss (up to 22% vs 15%) through dual receptor activation, but semaglutide has longer real-world data, more approved indications, and an oral formulation. Choice depends on goals, access, and physician guidance.